Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • HLA Today
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Research and News
    • Browse Research
      • Pre-transplant blinatumomab reduces MRD, time to HCT for pediatric patients with B-ALL
      • Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL
    • Browse News
    • About Our Research
    • Transplant Enews
      • Advances in Transplant Enews
      • Resource Connection Enews
  • Resources and Education
    • HCT Presentation Slides
      • Hemaglobinopathies, Transplant Consultation Timing Guidelines
      • Myeloproliferative Neoplasms (MPN), Transplant Consultation Timing Guidelines
    • Patient Resources
    • Financial Resources
    • Materials Catalog
    • Obstetrician Resources
    • Education Catalog
      • Sickle Cell Disease: Exploring treatment options and psychosocial care
      • Continuing Education Discontinuation
      • Building Yourself From The Ground Up
    • Technique Video
    • Umbilical Cord Blood Collection Training for Public Donation
  • Browse Research
  • Browse News
  • About Our Research
  • Transplant Enews

  • Research and News
  • Browse Research
  • Email
  • Print This Page

Choose a Topic

  • All Topics
  • ASH 2017
  • AML
  • MDS
  • Lymphomas and CLL
  • Older Patient HCT
  • Sickle Cell Disease
  • Post-Transplant
  • GVHD
  • Patient Eligibility
  • CIBMTR Publications
  • Cord Blood
  • Pediatric HCT
  • ALL
  • CML
  • Multiple Myeloma
  • Neuroblastoma
  • Non-Malignant Disorders
  • HLA Matching
  • Preparative Regimens
  • BMT CTN Publications
  • Unrelated Donor HCT
  • ASH 2018
  • ASH 2020
- Collapse

Subscribe to E-News

Receive new research summaries monthly.

Subscribe Now

Related Resources

Browse News
CIBMTR Research
Education Activities
Back to Top

Recent Research

Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.

  • Allogeneic HCT improves 5-year survival for patients over 60 with AML in CR1

    December 2018

    Devillier R et al.  ASH Annual Meeting 2018 - Results from a recent multicenter analysis support hematopoietic cell transplantation (HCT) as a curative option for patients over 60 with acute myeloid leukemia. Researchers found that HCT improved relapse-free survival and overall survival for older patients at 5 years when compared with patients who did not undergo HCT. (Devillier R et al.  2018 ASH Annual Meeting)

    Read More

  • Survival has significantly improved in recent years for patients with AML undergoing HCT

    December 2018
    Canaani J, et al. Journal of Internal Medicine - Researchers analyzed outcomes of patients with acute myeloid leukemia who underwent hematopoietic cell transplantation (HCT) in the past 20 years. Patients who underwent HCT in more recent years experienced significantly improved overall survival and decreased non-relapse mortality.

    Read More

  • New Patient Care Coordination Model Addresses Complexities of HCT Therapy

    September 2017
    Khera N, et al. Blood Advances – A multi-disciplinary team has proposed a care coordination framework to deliver a continuum of care to hematopoietic cell transplantation (HCT) patients.

    Read More

  • 90% Survival, Low GVHD at Two Years after Alternative Donor HCT for SCD

    August 2017
    Gilman AL, et al. Blood Advances – A study of patients with symptomatic sickle cell disease (SCD) who underwent CD34+ cell-selected, T-cell–depleted peripheral blood HCT from a mismatched family member or unrelated donor has resulted in a 2-year overall survival rate of 90%.

    Read More

  • Is Cord Blood the Best Alternative Graft Source for Patients with Minimal Residual Disease?

    October 2016
    Milano F, et al. N Engl J Med – A retrospective study of 582 patients with acute leukemia or myelodysplastic syndromes has shown that umbilical cord blood may be a superior graft choice for the approximately 70% of patients who lack an HLA-matched related donor, especially if they are minimal residual disease positive (MRD+).

    Read More

  • Better 5-Year QOL after Marrow Transplant than after PBSC Transplant

    September 2016
    Lee SJ, et al. JAMA Oncol – A secondary analysis of 195 recipients from the randomized, multi-center (n=551) Blood and Marrow Transplant Clinical Trials Network trial (BMT CTN 0201), found that bone marrow (BM) recipients experienced significantly better psychological well-being and less burdensome chronic GVHD symptoms five years after HCT than peripheral blood stem cell (PBSC) recipients did.

    Read More

  • Pre-Transplant Emotional Support Contributes to Longer Survival

    September 2016
    Ehrlich KB, et al. Bone Marrow Transplant – Researchers have found that good pre-transplant emotional support predicts longer overall survival at 2 years.

    Read More

  • Higher Post-Relapse Survival with Related or Unrelated HCT than Haploidentical HCT

    August 2016
    Solh M, et al. Bone Marrow Transplant – This single-center study of 237 consecutive patients who relapsed after HCT found that one-year post-relapse survival (PRS) was significantly higher in patients receiving matched related and matched unrelated grafts compared to those receiving haploidentical donor transplants using post-transplant cyclophosphamide.

    Read More

  • Peripheral Blood Stem Cell Donors Recover More Quickly Than Bone Marrow Donors

    April 2016
    Burns LJ, et al. Biol Blood Marrow Transplant – A study of unrelated donor hematopoietic cell transplantation (HCT) in a phase 3 Blood and Marrow Transplant Clinical Trials Network (BMT CTN) trial has shown that peripheral blood stem cell donors recover more quickly than bone marrow donors.

    Read More

  • Higher Rates of Infection after Marrow Compared to PBSC Transplants

    April 2016
    Young J-A H, et al. Biol Blood Marrow Transplant – A study of unrelated donor hematopoietic cell transplantation (HCT) recipients in a phase 3 Blood and Marrow Transplant Clinical Trials Network (BMT CTN) trial has shown that bone marrow graft recipients had higher rates of bacterial and pre-engraftment infections than did peripheral blood stem cell (PBSC) recipients.

    Read More

  • Comparable Survival in Clinical Trial Participants vs. Nonparticipants

    August 2015
    Khera N, et al. Biol Blood Marrow Transplant — Do clinical trial participants have better outcomes than comparable patients who are not treated on a trial? A study by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) examined that question by analyzing outcomes of a large-scale, randomized study comparing peripheral blood with bone marrow transplantation from unrelated donors.

    Read More

  • Haploidentical vs. Matched Unrelated HCT for AML

    July 2015
    Ciurea SO, et al. Blood — This study of 2,174 adults with acute myeloid leukemia (AML) compared using haploidentical (n=192) and 8/8 HLA-matched unrelated donor (n=1,982) grafts.

    Read More

  • Review: How I Treat the Older Patient with AML

    January 2015
    Ossenkopple G, et al. Blood – In this installment of the “How I treat” series in Blood, the authors discuss the highly heterogeneous clinical biology of acute myeloid leukemia (AML) among patients and how those variations are relevant for prognosis and treatment choice.

    Read More

  • Progress Report: Update of BMT CTN State of the Science Symposium

    February 2014
    Ferrara JLM. Biol Blood Marrow Transplant – In this 2014 report, the author updates the status of the 11 hematopoietic cell transplantation (HCT) clinical trials identified as having the highest scientific priority at the 2007 State of the Science Symposium convened by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).

    Read More

  • Parallel Phase 2 Trials Confirm Utility of Both Haploidentical and Cord Blood HCT

    July 2011
    Brunstein CG, et al. Blood – Two concurrent multi-center phase 2 studies have confirmed the utility of using unrelated double umbilical cord blood (dUCB) or HLA-haploidentical donor bone marrow grafts in reduced-intensity hematopoietic cell transplantation (HCT).

    Read More

  • Email
  • Print This Page

Transplant Indications and Outcomes

  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • HLA Today

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources and Education

  • HCT Presentation Slides
  • Patient Resources
  • Financial Resources
  • Materials Catalog
  • Obstetrician Resources
  • Education Catalog
  • Technique Video
  • Umbilical Cord Blood Collection Training for Public Donation

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2021 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright

Choose a Topic

  • All Topics
  • ASH 2017
  • AML
  • MDS
  • Lymphomas and CLL
  • Older Patient HCT
  • Sickle Cell Disease
  • Post-Transplant
  • GVHD
  • Patient Eligibility
  • CIBMTR Publications
  • Cord Blood
  • Pediatric HCT
  • ALL
  • CML
  • Multiple Myeloma
  • Neuroblastoma
  • Non-Malignant Disorders
  • HLA Matching
  • Preparative Regimens
  • BMT CTN Publications
  • Unrelated Donor HCT
  • ASH 2018
  • ASH 2020